Ascendis Pharma A/S
DKFinancials
Valuation Metrics
Ascendis Pharma A/S's Market Cap is $14.62B. At end of 2025 it was $9.49B. Ranked #717 of 3,121 in US market (top 23%), #223 of 1,463 on NASDAQ (top 15%), #33 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.62B | US#717/3,121 Sec#33/266 |
| Revenue | $1.19B | US#1,785/3,121 Sec#48/266 |
| Net Income | $854M | US#609/3,121 Sec#21/266 |
| Total Assets | $2.68B | US#1,890/3,121 Sec#49/266 |
| Net Assets | $1.69B | US#1,370/3,121 Sec#43/266 |
| Employees | 1,189 | US#1,938/3,121 Sec#52/266 |
| Value | ||
| P/E | 17.13x | US#937/3,121 Sec#31/266 |
| P/B | 8.67x | US#2,577/3,121 Sec#189/266 |
| P/S | 12.28x | US#2,741/3,121 Sec#118/266 |
| EV/EBITDA | 160.86x | US#2,473/3,121 Sec#83/266 |
| FCF Yield | 2.60% | US#1,930/3,121 Sec#63/266 |
| Profitability | ||
| ROE | 50.63% | US#109/3,121 Sec#10/266 |
| ROA | 31.81% | US#29/3,121 Sec#7/266 |
| Op. Margin | 10.38% | US#1,565/3,121 Sec#62/266 |
| Revenue Growth | 114.85% | US#84/3,121 Sec#30/266 |
| Financial Health | ||
| Debt Ratio | 59.14% | US#666/3,121 Sec#145/266 |
| Total Debt | $528M | US#1,846/3,121 Sec#62/266 |
| FCF | $381M | US#1,025/3,121 Sec#35/266 |
| Cash | $954M | US#716/3,121 Sec#33/266 |
| Current Ratio | 2.99x | US#805/3,121 Sec#194/266 |
| Net Debt/EBITDA | -4.82x | US#75/3,121 Sec#4/266 |
| Performance | ||
| 1Y Return | 18.73% | US#1,168/3,121 Sec#156/266 |
| 1M Return | -8.82% | US#1,536/3,121 Sec#131/266 |
| From 52W High | -16.10% | US#1,154/3,121 Sec#78/266 |
| 1Y MDD | -17.62% | US#525/3,121 Sec#17/266 |
| Trading | ||
| Volume | 1,238,396 shares | US#1,452/3,121 Sec#155/266 |
| Trading Value | $296M | US#414/3,121 Sec#23/266 |
| Per Share | ||
| EPS | $13.82 | US#176/3,121 Sec#8/266 |
| BPS | $27.30 | US#973/3,121 Sec#19/266 |
Company Info
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.